Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

Little is known regarding the interaction between immune microenvironment and tumorbiology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatmentgene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like...

ver descrição completa

Detalhes bibliográficos
Autores: Ficarra, Guido, Prat Aparicio, Aleix, Conte, Pierfranco, Guarneri, Valentina, Griguolo, Gaia, Dieci, Maria Vittoria, Paré, Laia, Miglietta, Federica, Generali, Daniele, Frassoldati, Antonio, Cavanna, Luigi, Bisagni, Giancarlo, Piacentini, Federico, Tagliafico, Enrico, Cagossi, Katia
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/226145
Acesso em linha:https://hdl.handle.net/2445/226145
Access Level:Acceso aberto
Palavra-chave:Càncer de mama
Receptors d'hormones
Antígens tumorals
Breast cancer
Hormone receptors
Tumor antigens
Descrição
Resumo:Little is known regarding the interaction between immune microenvironment and tumorbiology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatmentgene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocytelevels than luminal tumors. Moreover, significant differences in immune infiltrate composition,assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatoryantitumor immune infiltrate composition than luminal ones.

Registros relacionados